Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in Multiple Myeloma: 30 Years in the Making. (PubMed, J Clin Oncol) - Sep 11, 2026 - "We trace the path from thalidomide's serendipitous repurposing to lenalidomide's establishment of the Rd backbone and maintenance paradigm and to pomalidomide's ability to retain efficacy after lenalidomide failure. We then focus on next-generation cereblon E3 ligase modulators (CELMoDs), including iberdomide and mezigdomide, designed to deepen cereblon modulation and overcome resistance. We summarize early clinical experience and ongoing randomized programs, discuss rational combinations with monoclonal antibodies, bispecific T-cell engagers, and chimeric antigen receptor T-cell therapies, and propose a pragmatic framework for positioning CELMoDs in an immunotherapy-rich treatment era."
Journal • Review • Hematological Malignancies • Multiple Myeloma • Oncology • Targeted Protein Degradation • CRBN
|
|
Abdul-Hamid Bazarbachi; Jean-Luc Harousseau; Mohamad Mohty; Suzanne Lentzsch; Thierry Facon
|